thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - thalidomid - multippelt myelom - immunsuppressive - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
pravachol 20 mg
orifarm as - pravastatinnatrium - tablett - 20 mg
pravachol 40 mg
2care4 aps - pravastatinnatrium - tablett - 40 mg
dexamethasone krka 4 mg
krka, d.d. novo mesto - deksametason - tablett - 4 mg
melphalan macure 50 mg
macure pharma aps - melfalanhydroklorid - pulver og væske til injeksjons-/infusjonsvæske, oppløsning - 50 mg
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
thalidomide lipomed
lipomed gmbh - thalidomid - multippelt myelom - immunsuppressive - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.